Patterns of leukemia incidence in the United States by subtype and demographic characteristics, 1997–2002

Yamamoto, Jennifer F.; Goodman, Marc T.

doi:10.1007/s10552-007-9097-2

Cited by 320 publications

(234 citation statements)

References 28 publications

Supporting

Mentioning

209

Contrasting

Unclassified

Order By: Relevance

“…15,16 Hlutfall karla á móti konum var um 2,1:1, en erlendar rannsóknir hafa sýnt hlutfall nálaegt 1,7:1.…”

Section: Umraeðurunclassified

“…1,14 Nýgengistölur CLL frá Bandaríkjunum eru 6,75/100.000 hjá körlum og 3,65/100.000 meðal kvenna en í Evrópu eru sambaerilegar tölur 5,87/100.000 meðal karla og 4,01/100.000 hjá konum. 15,16 Nýgengi CLL á Íslandi er ekki þekkt með vissu þar sem tölur Krabbameinsskrár byggja á greiningum á vefjasýnum á meinafraeðideild Landspítala, en skránni berast síður upplýsingar um greiningar gerðar með frumuflaeðirannsókn eða öðrum aðferðum. Samkvaemt Krabbameinsskrá virðist nýgengi langvinns hvítblaeðis (CLL og CML samanlagt) hér á landi vera Höfundar hafa útfyllt eyðublað um hagsmunatengsl.…”

unclassified

See 1 more Smart Citation

Langvinnt eitilfrumuhvítblæði á Íslandi árin 2003-2013: Nýgengi, aðdragandi greiningar og undanfari

Olafsson¹,

Steingrímsdóttir²,

Viðarsson³

et al. 2016

LBL

View full text Add to dashboard Cite

“…15,16 Hlutfall karla á móti konum var um 2,1:1, en erlendar rannsóknir hafa sýnt hlutfall nálaegt 1,7:1.…”

Section: Umraeðurunclassified

unclassified

Langvinnt eitilfrumuhvítblæði á Íslandi árin 2003-2013: Nýgengi, aðdragandi greiningar og undanfari

Olafsson¹,

Steingrímsdóttir²,

Viðarsson³

et al. 2016

LBL

View full text Add to dashboard Cite

“…The male-tofemale ratio is 2 to 1. 13,14,18,19,32 The affected lymphocytes are of B-cell lineage in 95% of cases that carry CD5. Onset is insidious, and the diagnosis is occasionally discovered after a blood cell count is obtained for another reason.…”

Section: Chronic Lymphocytic Leukemiamentioning

confidence: 99%

Combined chronic lymphocytic leukemia and prolactinoma: a rare occurrence in a patient presenting with pituitary apoplexy

Krisht

Palmer

Couldwell

2013

JNS

View full text Add to dashboard Cite

Pituitary involvement in B-cell CLL and pituitary apoplexy, independently, are 2 rare events. Their co-occurrence in addition to the presence of prolactin-secreting adenoma cells, however, has never been described in the literature. We present the case of a combined pituitary CLL and prolactinoma apoplexy in a 77-year-old man to highlight the importance of imaging the brain in patients with CLL who present with signs and symptoms of pituitary apoplexy. To the best of our knowledge, there are only 2 other reported cases of CLL manifesting as a pituitary mass lesion.11,21 The current case is the first instance of a combined pituitary CLL-prolactinoma presenting with pituitary apoplexy. This case illustrates the need to carefully evaluate pituitary tumor specimens from patients with CLL for small lymphocytic infiltration, notwithstanding the presence of pituitary adenoma cells. Case ReportHistory and Examination. This 77-year-old man with untreated CLL diagnosed 8 years earlier presented with a 2-day history of severe bifrontal headaches associated with nausea and vomiting, including left facial numbness and complete ophthalmoplegia of his left eye. Three weeks prior to his admission he was hospitalized at an outside hospital for a pulmonary embolus and discharged on a regimen of 5 mg of oral warfarin at bedtime along with subcutaneous injections of 115 mg of enoxaparin every 12 hours as a bridging therapy. At his initial examination at our institution, he was awake, alert, and fully oriented. Positive findings included complete dense ophthalmoplegia of the left eye, diminished facial sensation to all sensory modalities along the V1 and V2 distributions, and right eye blindness secondary to glaucoma. Visual acuity remained Combined chronic lymphocytic leukemia and prolactinoma: a rare occurrence in a patient presenting with pituitary apoplexy The authors describe a rare case of combined pituitary chronic lymphocytic leukemia (CLL) and prolactinoma in a 77-year-old man presenting with apoplexy. This case highlights the importance of evaluating the pituitary gland in patients with CLL who present with clinical manifestations of apoplexy as well as the need to carefully evaluate pathological specimens from the gland for the presence of lymphocytic cells in those patients. This is the first reported case of a combined CLL-prolactinoma pituitary lesion presenting with apoplexy.

show abstract

“…[1][2][3] Although CR rates may exceed 90% with upfront therapy for APL, as many as 15-30% of patients will relapse after initially receiving ATRA-and cytotoxic chemotherapy-based therapies. [4][5][6][7][8][9] Arsenic trioxide (ATO) is a more recent addition to the APL therapeutic arsenal.…”

Section: Introductionmentioning

confidence: 99%

Delayed hematopoietic recovery after auto-SCT in patients receiving arsenic trioxide-based therapy for acute promyelocytic leukemia: a multi-center analysis

Mannis

Logan

Leavitt

et al. 2014

Bone Marrow Transplant

View full text Add to dashboard Cite

A potential link between arsenic (ATO)-based therapy and delayed hematopoietic recovery after autologous hematopoietic SCT (HSCT) for acute promyelocytic leukemia (APL) has previously been reported. We retrospectively reviewed the clinical histories of 58 patients undergoing autologous HSCT for APL at 21 institutions in the United States and Japan. Thirty-three (56%) of the patients received ATO-based therapy prior to stem cell collection. Delayed neutrophil engraftment occurred in 10 patients (17%): 9 of the 10 patients (90%) received prior ATO (representing 27% of all ATO-treated patients), compared with 1 of the 10 patients (10%) not previously treated with ATO (representing 4% of all ATO-naïve patients; P o0.001). Compared with ATO-naïve patients, ATO-treated patients experienced significantly longer times to ANC recovery (median 12 days vs 9 days, P o 0.001). In multivariate analysis, the only significant independent predictor of delayed neutrophil engraftment was prior treatment with ATO (hazard ratio 4.87; P o 0.001). Of the available stem cell aliquots from APL patients, the median viable post-thaw CD34+ cell recovery was significantly lower than that of cryopreserved autologous stem cell products from patients with non-APL AML. Our findings suggest that ATO exposure prior to CD34+ cell harvest has deleterious effects on hematopoietic recovery after autologous HSCT.

show abstract

Patterns of leukemia incidence in the United States by subtype and demographic characteristics, 1997–2002

Abstract: Known risk factors are unlikely to explain the observed disparities in leukemia incidence. Further studies of differences in environmental and genetic risk factors in these populations by specific leukemia subtype may provide clues to the etiologies of these malignancies.

Cited by 320 publications

References 28 publications

Langvinnt eitilfrumuhvítblæði á Íslandi árin 2003-2013: Nýgengi, aðdragandi greiningar og undanfari

Langvinnt eitilfrumuhvítblæði á Íslandi árin 2003-2013: Nýgengi, aðdragandi greiningar og undanfari

Combined chronic lymphocytic leukemia and prolactinoma: a rare occurrence in a patient presenting with pituitary apoplexy

Delayed hematopoietic recovery after auto-SCT in patients receiving arsenic trioxide-based therapy for acute promyelocytic leukemia: a multi-center analysis

Contact Info

Product

Resources

About